TRAVERE THERAPEUTICS, INC. Convertible Debt, Current
TRAVERE THERAPEUTICS, INC. (TVTX) had Convertible Debt, Current of $0 as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ConvertibleDebtCurrent · last filed 2026-02-19
- 2025-12-31: Convertible Debt, Current $0.00.
- 2025-09-30: Convertible Debt, Current $0.00.
- 2025-06-30: Convertible Debt, Current $68.84M.
- 2025-03-31: Convertible Debt, Current $68.76M.
| Period end | Convertible Debt, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 |
| 2025-06-30 | $68.84M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $68.76M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $68.68M 10-K · filed 2026-02-19 |
| 2024-09-30 | $68.60M 10-Q · filed 2024-10-31 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-21 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-24 |
| 2019-09-30 | $0.00 10-Q · filed 2019-10-30 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-06 |
| 2019-03-31 | $22.54M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $22.46M 10-K · filed 2020-02-24 |
| 2018-09-30 | $22.38M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $45.40M 10-Q · filed 2018-08-03 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |